IGF-I/IGF-1 Antibody (997121) [Unconjugated]

Recombinant Human IGF-I/IGF-1 (Catalog # 291-G1) stimulates proliferation in the MCF-7 human breast cancer cell line in a dose-dependent manner (orange line), as measured by Resazurin (Catalog # AR002). Proliferation elicited by Recombinant Human IGF-I/IGF-1 (10 ng/mL) is neutralized (green line) by increasing concentrations of Rat Anti-Human IGF-I/IGF-1 Monoclonal Antibody (Catalog # MAB2912). The ND50 is typically 0.1-0.8 µg/mL.

• Reactivity: Hu
• Applications: B/N
• Clone: 997121
• Clonality: Monoclonal
• Host: Rat
• Conjugate: Unconjugated

IGF-I/IGF-1 Antibody (997121) [Unconjugated] Summary

• Immunogen: E. coli-derived recombinant human IGF-I/IGF-1
  Gly49-Ala118
  Accession # P05019
• Specificity: Detects human IGF-I/IGF-1 in direct ELISAs.
• Source: N/A
• Isotype: IgG2a
• Clonality: Monoclonal
• Host: Rat
• Purity Statement: Protein A or G purified from hybridoma culture supernatant
• Endotoxin Note: <0.10 EU per 1 μg of the antibody by the LAL method.

Applications/Dilutions

• Dilutions:
  • Neutralization 0.1-0.8 ug/mL

Packaging, Storage & Formulations

• Storage: Use a manual defrost freezer and avoid repeated freeze-thaw cycles.
  • 12 months from date of receipt, -20 to -70 °C as supplied.
  • 1 month, 2 to 8 °C under sterile conditions after reconstitution.
  • 6 months, -20 to -70 °C under sterile conditions after reconstitution.
• Buffer: Lyophilized from a 0.2 μm filtered solution in PBS with Trehalose. *Small pack size (SP) is supplied either lyophilized or as a 0.2 µm filtered solution in PBS.
• Reconstitution Instructions: Reconstitute at 0.5 mg/mL in sterile PBS.

Notes

This product is produced by and ships from R&D Systems, Inc., a Bio-Techne brand.

Alternate Names for IGF-I/IGF-1 Antibody (997121) [Unconjugated]

• IBP1
• IGF1
• IGF-1
• IGF1A
• IGFI
• IGF-I
• IGF-IA
• IGF-IB
• insulin-like growth factor 1 (somatomedin C)
• insulin-like growth factor 1
• insulin-like growth factor I
• insulin-like growth factor IA
• insulin-like growth factor IB
• Mechano growth factor
• MGF
• Somatomedin A
• Somatomedin C
• somatomedin-C

Background

Insulin-like growth factor I, also known as somatomedin C, is the dominant effector of growth hormone and is structurally homologous to proinsulin. Human IGF-I is synthesized as two precursor isoforms with N- and alternate C-terminal propeptides (1). These isoforms are differentially expressed by various tissues (1). The 7.6 kDa mature IGF-I is identical between isoforms and is generated by proteolytic removal of the N- and C-terminal regions. Mature human IGF‑I shares 94% and 96% aa sequence identity with mouse and rat IGF-I, respectively (2), and exhibits cross-species activity. It shares 64% aa sequence identity with mature human
IGF‑II. Circulating IGF‑I is produced by hepatocytes, while local IGF-I is produced by many other tissues in which it has paracrine effects (1). IGF-I induces the proliferation, migration, and differentiation of a wide variety of cell types during development and postnatally (3). IGF-I regulates glucose and fatty acid metabolism, steroid hormone activity, and cartilage and bone metabolism (4-7). It plays an important role in muscle regeneration and tumor progression (1, 8). IGF-I binds IGF‑I R, IGF-II R, and the insulin receptor, although its effects are mediated primarily by IGF-I R (9). IGF-I association with IGF binding proteins increases its plasma half‑life and modulates its interactions with receptors (10).

1. Philippou, A. et al. (2007) In Vivo 21:45.
2. Sandberg-Nordqvist, A.C. et al. (1992) Brain Res. Mol. Brain Res. 12:275.
3. Guvakova, M.A. (2007) Int. J. Biochem. Cell Biol. 39:890.
4. Clemmons, D.R. (2006) Curr. Opin. Pharmacol. 6:620.
5. Bluher, S. et al. (2005) Best Pract. Res. Clin. Endocrinol. Metab. 19:577.
6. Garcia-Segura, L.M. et al. (2006) Neuroendocrinology 84:275.
7. Malemud, C.J. (2007) Clin. Chim. Acta 375:10.
8. Samani, A.A. et al. (2007) Endocrine Rev. 28:20.
9. LeRoith, D. and S. Yakar (2007) Nat. Clin. Pract. Endocrinol. Metab. 3:302.
10. Denley, A. et al. (2005) Cytokine Growth Factor Rev. 16:421.

Limitations

This product is for research use only and is not approved for use in humans or in clinical diagnosis. Primary Antibodies are guaranteed for 1 year from date of receipt.

Publications for IGF-I/IGF-1 Antibody (MAB2912)(1)

Publication using MAB2912

• C Sorrentino, L D'Antonio, SL Ciummo, C Fieni, L Landuzzi, F Ruzzi, S Vespa, P Lanuti, LV Lotti, PL Lollini, E Di Carlo CRISPR/Cas9-mediated deletion of Interleukin-30 suppresses IGF1 and CXCL5 and boosts SOCS3 reducing prostate cancer growth and mortality Journal of hematology & oncology, 2022-10-13;15(1):145. 2022-10-13 [PMID: 36224639] (Neutralization, Human)

Bioinformatics

• Uniprot:
  • P05019()